Pila Pharma AB is a clinical stage biotech company developing a potent, selective TRPV1 antagonist, XEN-D0501, as treatment of the rare painful disease erythromelalgia, type 2 diabetes and obesity.
Pila Pharma is currently preparing for a capital raise to sponsor the next 2 phase 2a clinical trials with XEN-D0501:
A study in obese people with type 2 diabetes to explore safety of higher doses and 3 months treatment and possible effects on lowering blood glucose and bodyweight
A study in people with the rare disease erythromelalgia to explore effect on perceived pain
XEN-D0501 has been tested in 300 subjects in phase 1 and 2 and has a demonstrated good safety profile in healthy volunteers and in patients with overactive bladder disease, chronic cough or type 2 diabetes as well as efficacy in type 2 diabetics on improving glucose stimulated insulin secretion.
Recently, 13 week preclinical safety studies with XEN-D0501 completed without registration of side effects and the molecule can therefore progress to clinical trials of up to 3 months duration.
In July 2022, the company received US Orphan Drug Designation for XEN-D0501 as treatment as the rare and painful disease erythromelalgia.
The company is based in Malmö, Sweden and is listed on Nasdaq First North GM, Stockholm, since July 2021.
The company is whole owner of private Danish subsidiary Pila Pharma Danmark ApS, Denmark.
The company welcomes partners and investors for the next development stages.
LATEST COMPANY PRESENTATIONS AND INTERVIEWS
PIla Pharma CEO Dorte X. Gram discusses with financial markets expert Richard Busellato on the obesity market, considerations of investing in pharma and how future solutions could look like including Pila Pharma’s novel tablet based #TRPV1-antagonist treatment
Please, find the link to the video (in English) here
(01 December-2023)
Our CEO Dorte X. Gram presented the Company and ongoing Rights Issue at Aktiespararna event Stora Aktiedagen i Stockholm
Please, find the link to the video (in English) here
(27 November-2023)
Our CEO Dorte X. Gram presented the Company and ongoing Rights Issue to the Danish young-investor group “Unge Investorer”
Please, find the link to the video (in Denish) here
(27 November-2023)
Our CEO Dorte X. Gram presents at Redeye Life Science Day 2023
Please, find the link to the video (in English) here
(23 November-2023)
Proinvestor – Pila Pharma vil lave en tablet mod fedme og diabetes
En mere teknisk introduktion til PILA PHARMA
For more information, please visit the following link here
(16 November-2023)
Today we paid a visit to the impressive clinical site in Cambridge where we plan to carry out our next phase 2 trial with XEN-D0501 in obese people with diabetes.
Happy worlddiabetesday to all!
Please, find the link to the video (in English) here
(14 November-2023)
CEO & Founder Dorte X. Gram presents PILA PHARMA’s innovative take on an alternative route to treating obesity, diabetes and cardiovascular disease at the LSX Inv€$tival conference in London.
Please, find the link to the video (in English) here
(13 November-2023)
Dansk Aktionærforening: Kom med på rejsen mod mere effektiv fedmebehandling
En god introduktion til PILA PHARMA
For more information, please visit the following link here
(07 November-2023)
Presentation by PILA PHARMA CEO, Dr. Dorte X. Gram at the LSXNordic Congress on 11/10/2023 on the case of TRPV1 antagonist XEN-D0501 as a novel treatment of obesity and type-2 diabetes.
In the presentation, Dr. Gram presents some previously undisclosed data on a heartfailure marker (ANP) further strengthening the case for XEN-D0501 as a safe and potent molecule for its class with benificial cardiometabolic effects.
(19 Oct-2023)
(03 Oct-2023)
(29 Sep-2023)
On August 28, 2023 in Finans Stockholm, our CEO For Dorte X Gram gave some hints at how PILA PHARMA will proceed and be relevant with our TRPV1 antagonist treatment.
Please, find the link to the video (in English) here
(07 Sep-2023)
CEO of Pila Pharma, Dorte X. Gram, interviews Matt Sondag about the thoughts and challenges of a living with erythromelalgia, a rare disease with periods of intense pain.
Please, find the link to the video (in English) here
(2 June-2023)
News
Pila Pharma AB announces outcome in the rights issue
Read the press release (in English) here
(05 Dec-2023)
Read the press release (in English) here
(29 Nov-2023)
PILA PHARMA WILL PRESENT AT “STORA AKTIEDAGARNA” IN STOCKHOLM TOMORROW, 27 NOVEMBER 2023 AT 8:00 CET
Read the press release (in English) here
(26 Nov-2023)
PILA PHARMA ANNOUNCES PRECLINICAL RESEARCH COLLABORATION
Read the press release (in English) here
(26 Nov-2023)
Read the press release (in English) here
(17 Nov-2023)
Read the press release (in English) here
(07 Nov-2023)
PILA PHARMA PUBLISHES INTERIM REPORT (1 July – 30 September 2023)
Read the press release (in English) here
(25 Oct-2023)
PILA PHARMA’S BOARD OF DIRECTORS HAS RESOLVED TO CARRY OUT A RIGHTS ISSUE OF SHARES OF APPROXIMATELY SEK 26.2 MILLION
Read the press release (in English) here